Numinus Acquiring Novamind in First Major Psychedelics Merger
This deal will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.
This deal will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.
Researchers attempt to replicate findings from a 2017 study that found classic psychedelic use conferred reduced risk of past-year opioid dependence and abuse.
Clearmind Medicine CEO Adi Zuloff-Shani writes this guest blog about how a new psychoactive molecule called MEAI can treat alcoholism.
This week in psychedelic business news: Field Trip Health secures a patent; Core One Labs seeks more retail investors; a new CEO takes over GABA Therapeutics.
The 3rd annual Psychedelics Catalyst Summit at Queen’s University in Kingston, Ontario, will be available to live stream.
The electric pulses could be organized into “trains” that resemble human words, and a vocabulary of “up to 50 words” appears to be present.
Buy your tickets to the Benzinga Psychedelics Capital Conference on…
In today’s episode, Lana describes her journey from being a clinically-focused empiricist to eventually opening up to the possibilities of mystical states of consciousness, discusses how plant medicine can be effective for healing all levels of trauma, and updates us on her view of the clinical and spiritual perspectives of psychedelic-assisted psychotherapy.
In this interview, Psychedelic Spotlight talks with Anne Bethune, a…
How can someone legally access psychedelic therapy in Canada? This is the question that I ask David Harder, Founder and Co-CEO of ATMA.
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Not only will this be your chance to meet me, but also the legendary Paul Stamets!
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
By now, most people watching this video are probably aware of the potential for psychedelic medicines, when combined with therapy, such as psilocybin and MDMA to treat a variety of mental health conditions. But receiving this treatment is still difficult.
In Canada, in addition to clinical trials, there are a couple of avenues that a patient can go through to receive psychedelic therapy. The first is called the Section 56 exemption, which has allowed dozens of people suffering from anxiety relating to terminal illnesses to undergo psilocybin therapy.
There is also a new avenue called the Health Canada “Special Access Program”, though relatively few people have gone through that route so far.
In the interview, we also discuss David’s company, ATMA. ATMA is a company that trains therapists to conduct psychedelic therapies. They also conduct therapy themselves.
Lastly, we discuss the upcoming Catalyst Psychedelic conference, happening in Kingston, Ontario between May 20-23rd. I will be there, and I hope to see you also!
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.